Wedoany.com Report on Feb 10th, HemostOD announced that it has secured CHF 2 million (approximately USD 2.5 million) in funding from the Swiss innovation agency Innosuisse to advance the preclinical research of its universal, donor-free platelets. The company focuses on producing platelet products independent of donors through in vitro manufacturing technology.

Faouzi Khechana, CEO of HemostOD, stated, "This non-dilutive funding will help us address the global shortage of platelet supply. Our technology platform can manufacture platelet products with higher safety and lower cost, offering a promising new solution for clinical treatment." The company's donor-free platelet technology targets the needs of patients such as those with cancer, trauma, and undergoing surgery, with an estimated market size of USD 5.7 billion.

The secured funds will support the company in achieving key development goals, including establishing a pilot production line to validate technology scalability and engaging in pre-Investigational New Drug application discussions with the U.S. Food and Drug Administration. The Innosuisse funding program is highly competitive, with only about 10% of applicants receiving approval.

Khechana added, "We are grateful for Innosuisse's recognition of HemostOD's technological innovation capabilities. We can produce universal, donor-free platelets on-demand within two hours. This innovative approach will help improve patient care in the field of transfusion medicine." The company's technology is based on a proprietary bioreactor system that utilizes immortalized hematopoietic stem cells to generate platelets in vitro.

HemostOD has been granted 14 patents worldwide and plans to advance product development in the U.S. and European markets. The company's donor-free platelet technology aims to create new opportunities in transfusion medicine by enhancing product accessibility and safety.